JCO Article Insights: Adoption of Capivasertib in Metastatic Hormone Receptor–Positive, HER2-Negative Breast Cancer – Efficacy, Toxicity and Treatment Sequencing
Dec 30 2024
9 mins
In this JCO Article Insights episode, Giselle de Souza Carvalho provides a summary on "Navigating Treatment Pathways in Metastatic Hormone Receptor–Positive, HER2-Negative Breast Cancer: Optimizing Second-Line Endocrine and Targeted Therapies" by Bhardwarj, et al and "US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor–Positive,